- Home
- »
- Medical Devices
- »
-
Pharmaceutical Analytical Testing Services In CRO Market, 2033GVR Report cover
![Pharmaceutical Analytical Testing Services In CRO Market (2026 - 2033)Report]()
Pharmaceutical Analytical Testing Services In CRO Market (2026 - 2033)
Size, Share & Trends Analysis Report By Service (Bioanalytical Testing, Method Development & Validation), By End-use (Pharmaceutical Companies, Biopharmaceutical Companies), By Region, And Segment Forecasts,
Market Size, 2025
$8.0BMarket Estimate, 2026
$8.7BMarket Forecast, 2033
$15.9BCAGR, 2026–2033
9.1%Pharmaceutical Analytical Testing Services In CRO Market Summary
The global pharmaceutical analytical testing services in CRO market size was valued at USD 8.0 billion in 2025 and is projected to grow from USD 8.7 billion in 2026 to USD 15.9 billion by 2033, at a CAGR of 9.1% from 2026 to 2033. North America dominated the market, accounting for the largest share of 37.2% in 2025.
Key Market Trends & Insights
- By service: Bioanalytical testing held the largest revenue share of 38.5% in 2025
- By end-use: Pharmaceutical companies held the largest revenue share of 45.7% in 2025
Regional Highlights
- Largest regional market: North America (37.2% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market Size in 2025: USD 8.0 Billion
- Estimated Market Size in 2026: USD 8.7 Billion
- Projected Market Size by 2033: USD 15.9 Billion
- CAGR (2026-2033): 9.1%
The pharmaceutical analytical testing services in CRO industry is anticipated to grow over the forecast period owing to increasing outsourcing of analytical testing by pharmaceutical and biotechnology companies, stringent global regulatory requirements for product quality and safety, rising development of biologics, biosimilars, and advanced therapies, growing pharmaceutical research and development activities, and expanding demand for specialized analytical capabilities across the drug development lifecycle. The market growth is further supported by the need to reduce development timelines, optimize operational costs, and access advanced analytical technologies without major capital investment. The increasing complexity of pharmaceutical formulations and regulatory expectations continues to drive the outsourcing of analytical testing services to specialized CROs.
The increasing outsourcing of pharmaceutical analytical testing remains one of the primary growth drivers for the market. The growing complexity of drug development, coupled with strict regulatory requirements for analytical method validation, stability testing, impurity profiling, and bioanalytical assessments, has encouraged pharmaceutical companies to partner with specialized CROs that offer advanced laboratory infrastructure and regulatory expertise. The outsourcing model enables companies to reduce operational costs, improve resource utilization, and accelerate product development timelines while maintaining regulatory compliance. For instance, in May 2025, SGS announced ISO 17025 accreditation for its pharmaceutical laboratory in Mississauga, Canada, enabling the facility to provide extractables and leachables testing services for pharmaceutical, biopharmaceutical, and medical device manufacturers across North America, thereby expanding analytical testing capacity to address increasing client demand.
The increasing development of biologics, biosimilars, cell and gene therapies, and other complex drug modalities is another significant factor supporting market growth. These products require sophisticated analytical characterization, bioanalytical testing, stability assessment, and regulatory documentation throughout development and commercialization, creating sustained demand for specialized CRO services. The growing number of clinical development programs involving complex biologics has further increased the need for advanced analytical technologies and scientific expertise. For instance, in June 2025, Svar Life Science and Lablytica Life Science entered a strategic partnership to expand regulated bioanalytical services with advanced LC-MS-MS capabilities for pharmacokinetic, pharmacodynamic, biomarker quantification, and therapeutic drug monitoring studies across drug discovery and clinical development programs.
The market growth is moderated by high investment requirements for advanced analytical laboratories, evolving regulatory expectations, and the limited availability of highly skilled analytical scientists with expertise in complex testing methodologies. The increasing pipeline of biologics and advanced therapies, continued outsourcing by emerging biotechnology companies, and ongoing investments in analytical laboratory expansion and regulatory consulting services are expected to create significant growth opportunities for pharmaceutical analytical testing service providers. The combination of increasing pharmaceutical outsourcing, expanding biologics development, stringent quality requirements, and continuous investments in analytical capabilities is expected to support the sustained market growth over the forecast period.
Market Dynamics
The increasing outsourcing of pharmaceutical analytical testing activities is a major driver for the pharmaceutical analytical testing services in CRO market. Pharmaceutical and biotechnology companies are increasingly relying on specialized CROs to perform analytical method development, method validation, stability studies, extractables and leachables testing, elemental impurity analysis, microbiological testing, and batch release testing throughout the drug development lifecycle. Outsourcing enables sponsors to reduce infrastructure investment, improve operational flexibility, accelerate development timelines, and gain access to advanced analytical technologies and regulatory expertise. The growing number of small and mid-sized biotechnology companies with limited in-house laboratory capabilities is further supporting outsourcing demand. In addition, increasing regulatory expectations for product quality, data integrity, and comprehensive analytical documentation continue to encourage long-term partnerships with specialized analytical testing service providers.
The shortage of skilled analytical scientists remains a significant restraint for the pharmaceutical analytical testing services in CRO market. Advanced analytical testing requires highly qualified professionals with expertise in chromatography, mass spectrometry, spectroscopy, microbiology, method validation, regulatory compliance, and interpretation of complex analytical data. The increasing adoption of biologics, cell and gene therapies, and other advanced pharmaceutical products has further increased the need for specialized technical expertise that is not readily available across all regions. The limited availability of experienced professionals may extend project timelines, reduce laboratory efficiency, and increase operating costs for CROs. In addition, continuous changes in regulatory expectations require ongoing workforce training, creating additional operational challenges for analytical testing service providers.
The increasing development of biologics, biosimilars, cell therapies, gene therapies, and other advanced therapeutic products presents a significant opportunity for the pharmaceutical analytical testing services in CRO market. These complex products require extensive analytical characterization, impurity profiling, bioanalytical testing, stability assessment, and comparability studies throughout development and commercialization. The growing clinical pipeline of advanced therapies is increasing demand for specialized analytical platforms and regulatory-compliant testing services that many pharmaceutical companies prefer to outsource. Furthermore, continued investments in advanced analytical technologies, expansion of biologics manufacturing, and increasing regulatory requirements for product characterization are expected to create long-term opportunities for CROs offering integrated pharmaceutical analytical testing services.
Market Concentration & Characteristics
The pharmaceutical analytical testing services in CRO market growth stage is high, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion. Innovation remains a key competitive factor in the market, with service providers investing in advanced analytical instrumentation, laboratory automation, digital data management platforms, and high sensitivity bioanalytical technologies. The increasing complexity of biologics, biosimilars, cell and gene therapies, and other advanced pharmaceutical products is encouraging the adoption of sophisticated analytical methods that improve testing accuracy, laboratory productivity, regulatory compliance, and turnaround times across the drug development lifecycle.
Mergers and acquisitions continue to shape the pharmaceutical analytical testing services in CRO industry by expanding laboratory capacity, strengthening scientific expertise, and broadening analytical service portfolios. Strategic acquisitions enable CROs to enhance capabilities in bioanalytical testing, stability studies, elemental impurity analysis, microbiological testing, and regulatory support while expanding their geographic presence. These transactions also improve operational scale, diversify client relationships, and strengthen competitive positioning within the global pharmaceutical outsourcing industry.
Regulatory compliance remains a major factor influencing the pharmaceutical analytical testing services in CRO market. Analytical service providers are required to comply with current Good Manufacturing Practices, Good Laboratory Practices, International Council for Harmonization guidelines, data integrity requirements, and regulations established by global health authorities. Compliance with stringent analytical validation, documentation, quality assurance, and laboratory accreditation requirements increases operational complexity while creating competitive advantages for CROs with established quality management systems and regulatory expertise.
Pharmaceutical analytical testing CROs are expanding their service portfolios to provide integrated analytical solutions throughout the pharmaceutical development lifecycle. Many organizations now offer analytical method development, method validation, stability testing, bioanalytical services, microbiological testing, extractables and leachables analysis, elemental impurity testing, and regulatory documentation through a single platform. Integrated service offerings improve project coordination, simplify outsourcing, and enable faster progression from early development through commercial manufacturing.
Regional expansion continues to strengthen the global presence of pharmaceutical analytical testing CROs. Companies are establishing new analytical laboratories and expanding existing facilities across North America, Europe, and the Asia Pacific to address increasing pharmaceutical research, biologics development, and regulatory testing requirements. Geographic expansion improves laboratory capacity, enhances supply chain resilience, supports regional regulatory compliance, and enables analytical testing service providers to serve global pharmaceutical and biotechnology companies more efficiently.
Analyst Perspective
The pharmaceutical analytical testing services in CRO market is experiencing steady growth driven by increasing pharmaceutical outsourcing, expanding biologics and advanced therapy development, and rising regulatory requirements for product quality and safety. The increasing complexity of biologics, biosimilars, cell and gene therapies, vaccines, and specialty pharmaceuticals is driving demand for bioanalytical testing, method development and validation, stability testing, microbiological testing, impurity analysis, and regulatory support across the drug development lifecycle. Furthermore, companies with comprehensive analytical capabilities, accredited laboratory networks, advanced scientific expertise, and strong regulatory compliance are expected to strengthen their market position and support sustained market growth over the forecast period.
Impact of the U.S. Tariffs on the Global Pharmaceutical Analytical Testing Services in CRO Market
The current U.S. tariff environment has increased costs for imported laboratory instruments, analytical reagents, reference standards, laboratory consumables, and pharmaceutical testing equipment used by analytical testing service providers. CROs that depend on imported chromatography systems, mass spectrometers, laboratory chemicals, and specialized testing materials are experiencing higher procurement costs and, in some cases, longer sourcing timelines. These cost increases may raise operating expenses and gradually affect pricing for outsourced analytical testing services, particularly for highly specialized studies requiring sophisticated analytical platforms.
The market continues to maintain stable demand despite these cost pressures, supported by increasing pharmaceutical outsourcing, expanding biologics development, and stringent regulatory requirements for product quality testing. Many CROs are strengthening regional supplier networks, increasing procurement from domestic manufacturers where feasible, and investing in laboratory automation to improve operational efficiency. Continued investments in local laboratory infrastructure and diversified sourcing strategies are expected to reduce supply chain risks and support sustained growth of the global pharmaceutical analytical testing services in CRO industry over the long term.
Technological Advancements
Technological advancements continue to improve the capabilities of the pharmaceutical analytical testing services in CRO industry by increasing testing accuracy, laboratory efficiency, regulatory compliance, and analytical capacity across the drug development lifecycle. The adoption of advanced analytical instrumentation, automated laboratory operations, digital data management systems, and specialized bioanalytical platforms is enabling CROs to deliver comprehensive testing services for increasingly complex pharmaceutical products. These technologies are supporting higher productivity, improved data quality, and greater operational consistency while addressing the analytical requirements of small molecules, biologics, biosimilars, and advanced therapies.
The increasing complexity of pharmaceutical pipelines is encouraging analytical service providers to expand investments in modern laboratory infrastructure and specialized analytical platforms that can support evolving regulatory standards. Furthermore, continuous improvements in analytical sensitivity, workflow integration, and laboratory digitalization are strengthening the ability of CROs to manage larger project volumes with greater efficiency. The expanding adoption of these technologies across pharmaceutical research, clinical development, manufacturing support, and commercial quality testing is expected to strengthen service capabilities, improve client confidence, and support the long-term growth of the pharmaceutical analytical testing services in CRO market.
Pricing Model Analysis
The pricing structure within the pharmaceutical analytical testing services in CRO market varies according to project complexity, testing requirements, laboratory resource utilization, and the duration of client engagement. Fixed project pricing remains suitable for well-defined analytical programs with established deliverables, while per-sample pricing is extensively used for standardized routine testing activities. Time-and-material agreements provide flexibility for projects with changing analytical requirements, while dedicated laboratory support contracts address the long-term analytical needs of pharmaceutical and biotechnology companies. The increasing complexity of pharmaceutical products, expanding biologics development, and evolving regulatory requirements are encouraging analytical service providers to adopt pricing structures that align with specialized testing demands and resource allocation.
Furthermore, long-term outsourcing partnerships are contributing to greater pricing stability by enabling efficient laboratory planning and optimized capacity utilization. The continued expansion of pharmaceutical research and manufacturing activities across global markets is expected to support the use of multiple pricing approaches, allowing CROs to address varying client requirements while maintaining operational efficiency and sustainable service delivery across the pharmaceutical analytical testing services market.
Service Insights
The bioanalytical testing segment led the pharmaceutical analytical testing services in CRO market with the largest revenue share of 38.5% in 2025. The segment's dominance is attributed to the growing development of biologics, biosimilars, vaccines, and complex therapeutic products that require extensive pharmacokinetic, pharmacodynamic, immunogenicity, and biomarker analyses during preclinical and clinical development. Pharmaceutical and biotechnology companies are increasingly outsourcing bioanalytical testing to specialized CROs to access advanced analytical technologies, regulatory expertise, and validated testing capabilities while reducing internal laboratory investments.
The stability testing segment is projected to register a significant CAGR during the forecast period. The growth is driven by increasing regulatory requirements for stability studies throughout product development, approval, and commercial manufacturing. The expanding pipeline of biologics, biosimilars, and specialty pharmaceuticals has increased demand for long-term, accelerated, and in-use stability studies to establish product shelf life and storage conditions. Rising outsourcing of quality testing activities and increasing pharmaceutical manufacturing are expected to further support segment growth.
End-use Insights
The pharmaceutical companies segment led the pharmaceutical analytical testing services in CRO industry with the largest revenue share of 45.7% in 2025. The segment is driven by increasing outsourcing of analytical testing across drug discovery, clinical development, manufacturing, and post-approval quality control activities. Pharmaceutical companies increasingly collaborate with CROs to obtain specialized analytical expertise, improve development efficiency, meet global regulatory requirements, and optimize operational costs. The continued expansion of small molecule drug development further supports the demand for outsourced analytical testing services.
The biopharmaceutical companies segment is anticipated to witness the fastest CAGR during the forecast period. The growing development of monoclonal antibodies, recombinant proteins, cell therapies, gene therapies, and other advanced biologics is driving increased demand for specialized analytical characterization and bioanalytical testing services. Many biopharmaceutical companies prefer outsourcing these activities to CROs with advanced analytical platforms and regulatory expertise, supporting rapid segment expansion over the forecast period.
Regional Insights
North America dominated the pharmaceutical analytical testing services in CRO market with the largest revenue share of 37.2% in 2025. The market is supported by increasing pharmaceutical research and development activities, expanding biologics and biosimilars pipeline, and rising outsourcing of analytical testing by pharmaceutical and biotechnology companies. The presence of leading CROs, advanced laboratory infrastructure, and stringent regulatory requirements for product quality and safety continues to support market demand. In addition, growing investments in advanced analytical technologies and increasing clinical development activities are expected to contribute to sustained market growth over the forecast period.
U.S. Pharmaceutical Analytical Testing Services In CRO Market Trends
The U.S. pharmaceutical analytical testing services in CRO industry held the largest share of North America in 2025. Market growth is supported by a large pharmaceutical and biotechnology industry, increasing development of biologics and advanced therapies, and strong demand for outsourced analytical testing services. Furthermore, stringent regulatory standards, continued investment in pharmaceutical innovation, and the presence of major CROs with advanced analytical capabilities are expected to support long-term market expansion.
The Canada pharmaceutical analytical testing services in CRO market is expected to grow at a significant CAGR during the forecast period. The market is growing steadily owing to increasing clinical research activities, expansion of pharmaceutical manufacturing, and rising outsourcing of analytical testing services. The country's skilled scientific workforce, regulatory compliance framework, and growing investments in life sciences research continue to support demand for specialized analytical testing throughout the pharmaceutical development lifecycle.
Europe Pharmaceutical Analytical Testing Services in CRO Market Trends
The Europe pharmaceutical analytical testing services in CRO industry is experiencing steady growth, supported by a well-established pharmaceutical industry, increasing development of biologics and specialty pharmaceuticals, and stringent regulatory standards governing pharmaceutical quality. Growing investments in drug development, expanding clinical trials, and increasing outsourcing of analytical testing services are supporting market expansion. The presence of established CROs and continuous investment in advanced analytical laboratories are expected to strengthen regional growth over the forecast period.
The pharmaceutical analytical testing services in CRO market in Germany is supported by its strong pharmaceutical manufacturing sector, advanced analytical laboratory infrastructure, and increasing demand for regulatory compliant testing services. Rising investment in biologics development, quality assurance, and pharmaceutical exports is further supporting demand for outsourced analytical testing across the country.
The UK Pharmaceutical Analytical Testing Services in CRO market is expected to grow steadily over the forecast period. Market expansion is supported by a strong biotechnology ecosystem, increasing pharmaceutical innovation, and the presence of leading CROs offering comprehensive analytical testing services. Continued investments in life sciences research, advanced laboratory technologies, and biologics development are expected to support sustained market growth.
Asia Pacific Pharmaceutical Analytical Testing Services in CRO Market Trends
The Asia Pacific pharmaceutical analytical testing services in CRO industry is anticipated to register significant growth owing to expanding pharmaceutical manufacturing, increasing clinical research activities, rising contract research outsourcing, and growing investments in biotechnology. The availability of skilled scientific professionals, cost-competitive laboratory services, and expanding regulatory capabilities continues to attract global pharmaceutical companies seeking analytical testing support.
The Japan pharmaceutical analytical testing services in CRO market is growing steadily owing to increasing development of innovative pharmaceuticals, expanding biologics research, and stringent quality requirements for drug approval. The country's advanced pharmaceutical industry and increasing collaboration between pharmaceutical companies and CROs continue to support demand for specialized analytical testing services.
The pharmaceutical analytical testing services in CRO market in China is expected to witness significant growth over the forecast period. The rapid expansion of pharmaceutical manufacturing, increasing investment in biotechnology research, and rising outsourcing by domestic and international pharmaceutical companies are driving market growth. Continued development of analytical laboratory infrastructure and regulatory modernization are further supporting market expansion.
The India pharmaceutical analytical testing services in CRO market is anticipated to grow at a notable pace owing to increasing pharmaceutical production, expanding generic and biologics manufacturing, and growing global outsourcing of analytical testing services. The country's cost-competitive laboratory operations, skilled scientific workforce, and expanding CRO industry continue to strengthen its position as a preferred destination for pharmaceutical analytical testing.
Latin America Pharmaceutical Analytical Testing Services in CRO Market Trends
The Latin America pharmaceutical analytical testing services in CRO industry is experiencing gradual growth supported by increasing pharmaceutical manufacturing, improving regulatory standards, and rising outsourcing of laboratory testing services. Growing investments in healthcare infrastructure and the expansion of clinical research activities are expected to drive increased demand for analytical testing services across the region.
The Brazil pharmaceutical analytical testing services in CRO market accounted for the largest share in Latin America in 2025. Market growth is supported by the expansion of domestic pharmaceutical manufacturing, increasing clinical development activities, and rising regulatory requirements for analytical quality testing. Continued investment in laboratory infrastructure and increasing collaboration with international pharmaceutical companies are expected to support future market expansion.
Middle East & Africa Pharmaceutical Analytical Testing Services in CRO Market Trends
The Middle East & Africa pharmaceutical analytical testing services in CRO industry is witnessing gradual growth owing to increasing pharmaceutical investments, improving healthcare infrastructure, and expanding regulatory oversight of pharmaceutical quality. The growing demand for outsourced analytical testing services and the increasing pharmaceutical manufacturing activities are expected to support regional market growth over the forecast period.
The UAE pharmaceutical analytical testing services in CRO market is expected to register steady growth over the forecast period. The market is supported by increasing investments in pharmaceutical manufacturing, expansion of healthcare and life sciences infrastructure, and government initiatives aimed at strengthening domestic pharmaceutical capabilities. Rising demand for regulatory-compliant analytical testing and growing collaboration with international pharmaceutical companies are expected to contribute to sustained market growth.
Key Pharmaceutical Analytical Testing Services In CRO Company Insights
The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in October 2025, Eurofins Viracor BioPharma Services commissioned a new 8,800 m² laboratory in Lenexa, Kansas, dedicated to specialty bioanalytical and biomarker services. The facility expands Eurofins' capabilities in oncology, infectious diseases, autoimmune disorders, cell and gene therapy, biologics, and LC-MS bioanalytical testing, strengthening its pharmaceutical analytical testing service portfolio.
Key Pharmaceutical Analytical Testing Services In CRO Companies
The following key companies have been profiled for this study of the pharmaceutical analytical testing services in CRO market.
-
SGS Société Générale de Surveillance SA
-
Worldwide Clinical Trials
-
Sofpromed
-
ClinChoice
-
Evotec
-
Eurofins Scientific
-
KYMOS Group
-
ViviaBiotech S.L.
-
GalChimia
-
TCI Laboratories
-
Cotecna (NEOTRON SpA,)
-
Tentamus
-
Enzymlogic
-
Pharmbiotest
-
UNIFARM - Research Centre
-
ANAPHARM EUROPE, S.L.U
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Eurofins Scientific, SGS SA)
Mature market participants focus on expanding global analytical laboratory networks and providing integrated pharmaceutical analytical testing services across drug discovery, clinical development, manufacturing, and commercial quality control. These companies offer comprehensive capabilities, including bioanalytical testing, method development and validation, stability testing, microbiological testing, elemental impurity analysis, extractables and leachables studies, and regulatory support through accredited laboratories.
Established players benefit from extensive global laboratory infrastructure, broad analytical technology platforms, experienced scientific teams, and strong regulatory expertise. Their ability to support multinational pharmaceutical companies through standardized quality systems, regulatory-compliant testing, and integrated laboratory services enables them to secure long-term outsourcing agreements across multiple therapeutic areas.
Established players face challenges related to high operating costs, continuous investment in advanced analytical instrumentation, laboratory modernization, and maintaining compliance with evolving global regulatory requirements. Large laboratory networks may also reduce operational flexibility and extend decision-making and project implementation timelines compared with smaller specialized CROs.
Emerging Players (KYMOS Group)
Emerging participants primarily focus on specialized analytical capabilities, including bioanalytical testing, biomarker analysis, immunogenicity assessment, cell-based assays, and analytical support for biologics and advanced therapies. Many invest in niche scientific expertise, advanced analytical platforms, and strategic collaborations with pharmaceutical and biotechnology companies to strengthen their market presence and expand service offerings.
Emerging players gain competitive advantages through specialized scientific expertise, flexible laboratory operations, customized project execution, and faster response times. Their focused analytical capabilities and close customer engagement enable them to efficiently support small and mid-sized pharmaceutical and biotechnology companies with complex analytical requirements.
Emerging players often face limitations in laboratory capacity, international presence, financial resources, and broad service integration. Limited global regulatory experience, dependence on a smaller client base, and the need for continuous investment in advanced analytical technologies may restrict expansion into large multinational pharmaceutical outsourcing programs.
Recent Developments
-
In May 2025, SGS announced that its pharmaceutical laboratory in Mississauga, Canada, received ISO/IEC 17025 accreditation for extractables and leachables testing. The accreditation expands SGS's analytical testing capabilities for pharmaceutical, biopharmaceutical, and medical device manufacturers while strengthening its regulated laboratory services in North America.
Pharmaceutical Analytical Testing Services in CRO Market Report Scope
Report Attribute
Details
Market size in 2025
USD 8.0 billion
Estimated market size in 2026
USD 8.7 billion
Projected market size by 2033
USD 15.9 billion
Growth rate
CAGR of 9.1% from 2026 to 2033
Actual data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Service, end-use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Poland; Switzerland; Austria; Czech Republic; Croatia; Slovenia; Greece; Japan; China; India; Australia; Thailand; South Korea; Brazil; Argentina; South Africa; UAE; Saudi Arabia; Kuwait; Qatar; Oman
Key companies profiled
SGS Société Générale de Surveillance SA; Worldwide Clinical Trials; Sofpromed; ClinChoice; Evotec; Eurofins Scientific; KYMOS Group; ViviaBiotech S.L.; GalChimia; TCI Laboratories; Cotecna (NEOTRON SpA); Tentamus; Enzymlogic; Pharmbiotest; UNIFARM - Research Centre; ANAPHARM EUROPE, S.L.U
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Pharmaceutical Analytical Testing Services In CRO Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical analytical testing services in CRO market report based on service, end-use, and region:
-
Service Outlook (Revenue, USD Million, 2021 - 2033)
-
Bioanalytical Testing
-
Clinical
-
Non-Clinical
-
-
Method Development & Validation
-
Extractable & Leachable
-
Impurity Method
-
Technical Consulting
-
Others
-
-
Stability Testing
-
Drug Substance
-
Stability Indicating Method Validation
-
Accelerated Stability Testing
-
Photostability Testing
-
Others
-
-
Others
-
-
End-use Outlook (Revenue, USD Million, 2021 - 2033)
-
Pharmaceutical Companies
-
Biopharmaceutical Companies
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
Poland
-
Switzerland
-
Austria
-
Czech Republic
-
Croatia
-
Slovenia
-
Greece
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
UAE
-
Saudi Arabia
-
Kuwait
-
Qatar
-
Oman
-
-
Research Methodology
The pharmaceutical analytical testing services in CRO market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each pharmaceutical analytical testing services in CRO segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Service
Revenue Capture Definition
Bioanalytical Testing
The segment captures revenue generated from bioanalytical testing services provided for pharmaceutical and biopharmaceutical products throughout preclinical and clinical development. Services include pharmacokinetic and pharmacodynamic analysis, biomarker quantification, immunogenicity assessment, ligand binding assays, and bioanalytical method validation.
Clinical
The segment captures revenue generated from bioanalytical testing services conducted to support clinical trials. Services include analysis of clinical samples, pharmacokinetic studies, biomarker testing, immunogenicity assessment, therapeutic drug monitoring, and regulatory-compliant bioanalysis across Phase I to Phase IV clinical studies.
Non-Clinical
The segment captures revenue generated from bioanalytical testing services supporting nonclinical drug development. Services include toxicokinetic analysis, pharmacokinetic evaluation, biomarker studies, bioanalytical method development, and sample analysis for animal studies conducted prior to clinical evaluation.
Method Development & Validation
The segment captures revenue generated from analytical method development and validation services for pharmaceutical products. Services include method optimization, validation of analytical procedures, method transfer, robustness studies, accuracy and precision assessment, and regulatory documentation supporting product development and commercial manufacturing.
Extractable & Leachable
The segment captures revenue generated from extractables and leachables testing services performed to identify and quantify chemical compounds released from packaging materials, delivery systems, manufacturing equipment, and container closure systems that may affect pharmaceutical product quality and patient safety.
Impurity Method
The segment captures revenue generated from impurity method development and analytical testing services used to detect, identify, quantify, and characterize process related impurities, degradation products, residual solvents, elemental impurities, and other contaminants in pharmaceutical products in accordance with regulatory requirements.
Technical Consulting
The segment captures revenue generated from technical consulting services supporting pharmaceutical analytical testing. Services include analytical strategy development, laboratory investigations, regulatory consulting, method troubleshooting, quality system support, data review, and compliance guidance throughout pharmaceutical development and manufacturing.
Others (Method Development & Validation)
The segment captures revenue generated from other analytical method development and validation services, including analytical feasibility studies, technology transfer support, cleaning validation methods, dissolution method development, and customized analytical solutions not classified under other service categories.
Stability Testing
The segment captures revenue generated from stability testing services performed to evaluate the physical, chemical, microbiological, and biological stability of pharmaceutical products under defined storage conditions. Services support shelf life determination, storage condition evaluation, and regulatory submissions throughout product development and commercialization.
Drug Substance
The segment captures revenue generated from stability testing services performed on active pharmaceutical ingredients and drug substances. Services include long term, accelerated, stress, and intermediate stability studies to evaluate product integrity, degradation profiles, and compliance with regulatory stability requirements.
Stability Indicating Method Validation
The segment captures revenue generated from validation of stability-indicating analytical methods capable of accurately detecting changes in pharmaceutical products during stability studies. Services ensure analytical methods can distinguish active ingredients from degradation products and impurities under regulatory guidelines.
Accelerated Stability Testing
The segment captures revenue generated from accelerated stability testing services conducted under elevated temperature and humidity conditions to predict product shelf life, evaluate degradation pathways, and support regulatory submissions within shorter development timelines.
Photostability Testing
The segment captures revenue generated from photostability testing services performed to evaluate the effects of light exposure on pharmaceutical products. Services determine product stability under controlled light conditions in accordance with regulatory guidelines and support packaging selection and labeling requirements.
Others (Stability Testing)
The segment captures revenue generated from other stability testing services, including in use stability studies, freeze thaw stability studies, shipping stability assessments, container closure stability evaluation, and customized stability protocols developed to meet specific product requirements.
Others (Service)
The segment captures revenue generated from other pharmaceutical analytical testing services, including microbiological testing, environmental monitoring, batch release testing, raw material testing, dissolution testing, particulate analysis, elemental impurity testing, cleaning validation, and quality control services not included within the above service categories.
Segment - End Use
Revenue Capture Definition
Pharmaceutical Companies
The segment captures revenue generated from pharmaceutical companies outsourcing analytical testing services for small molecule drugs and specialty pharmaceutical products. Services include bioanalytical testing, method development and validation, stability studies, quality control testing, impurity analysis, and regulatory support across the drug development lifecycle.
Biopharmaceutical Companies
The segment captures revenue generated from biopharmaceutical companies outsourcing analytical testing services for biologics, biosimilars, monoclonal antibodies, recombinant proteins, vaccines, cell therapies, and gene therapies. Services include bioanalytical characterization, immunogenicity testing, biomarker analysis, stability testing, and analytical method validation supporting product development and commercialization.
Others
The segment captures revenue generated from analytical testing services provided to other end users, including contract development and manufacturing organizations, academic and research institutions, government laboratories, medical device manufacturers, and emerging biotechnology companies requiring specialized analytical support, quality testing, and regulatory compliance services.
Estimation Model
Bottom-Up Revenue Model
Laboratory Capacity Based Model
Drug Development Pipeline Demand Model
Outsourcing Penetration Model
- Market size is estimated by identifying major and emerging contract research organizations (CROs) that provide pharmaceutical analytical testing services, including bioanalytical testing, analytical method development and validation, stability testing, impurity analysis, extractables and leachables testing, microbiological testing, and regulatory analytical support.
- Revenue attributable to pharmaceutical analytical testing services is derived from annual reports, investor presentations, regulatory filings, company websites, laboratory service portfolios, and publicly disclosed business information.
- Company-level analytical testing revenues are aggregated and validated by evaluating laboratory footprint, analytical capabilities, service portfolio, client base, geographic presence, and industry benchmarks to estimate the overall market value.
- Market value is estimated using the analytical testing capacity available across CRO laboratories providing pharmaceutical analytical services.
- Key parameters evaluated include the number of analytical laboratories, scientific personnel, analytical instruments, laboratory utilization rates, annual sample processing capacity, and average pricing for analytical testing services across different study types.
- Total effective laboratory capacity is translated into potential annual revenue and cross-checked against laboratory expansion activities, utilization levels, client contracts, and publicly announced capacity investments.
- Market size is derived by evaluating the number of pharmaceutical and biopharmaceutical drug candidates progressing through discovery, preclinical, clinical, regulatory approval, and commercial manufacturing stages.
- Average analytical testing expenditure is assigned to each development stage for services including bioanalytical testing, analytical method development and validation, stability testing, impurity analysis, and regulatory testing and support.
- The number of drug development programs is multiplied by the estimated outsourced analytical testing expenditure, and the results are aggregated across oncology, infectious diseases, cardiovascular diseases, central nervous system disorders, metabolic diseases, immunology, rare diseases, and other therapeutic areas to estimate total market demand.
- Market size is estimated by assessing the proportion of pharmaceutical and biopharmaceutical companies that outsource analytical activities to CROs rather than maintain complete in-house analytical laboratories.
- Outsourcing rates are determined through primary interviews, industry publications, company disclosures, CRO partnership announcements, pharmaceutical research trends, and laboratory outsourcing practices.
- The addressable market is calculated by applying outsourcing penetration rates to total pharmaceutical analytical testing expenditure across bioanalytical testing, analytical method development and validation, stability testing, quality control testing, regulatory support, and related analytical services, thereby estimating the overall pharmaceutical analytical testing services opportunity.
Customization Table:
This report has been delivered with the following In-depth customizations
CLIENT REQUEST
CUSTOMIZATION DELIVERED
VALUE ADDS
Industry Outlook, Value Chain, and Business Model Assessment
Conducted a comprehensive evaluation of the pharmaceutical analytical testing services in CRO ecosystem, covering analytical instrument and laboratory equipment suppliers, reference standard and reagent providers, pharmaceutical and biotechnology companies, CROs, central laboratories, bioanalytical testing laboratories, stability testing facilities, regulatory consulting organizations, and quality assurance partners. Assessed prevailing outsourcing models, laboratory service workflows, revenue streams, pricing structures, testing demand across drug development stages, and value creation opportunities spanning method development, method validation, bioanalytical testing, stability studies, microbiological testing, and commercial quality control.
Provides a comprehensive understanding of the analytical testing ecosystem, outsourcing trends, revenue opportunities, and operational value drivers, enabling stakeholders to identify growth opportunities, optimize outsourcing strategies, and strengthen long term business planning across the pharmaceutical analytical testing services value chain.
Competitive Benchmarking and Analytical Capability Assessment
Performed detailed benchmarking of leading pharmaceutical analytical testing CROs based on analytical service portfolio, bioanalytical capabilities, laboratory infrastructure, regulatory compliance, quality management systems, analytical instrumentation, therapeutic expertise, global laboratory footprint, turnaround capabilities, and strategic collaborations. Included comparative assessment of integrated global CROs and specialized analytical laboratories supporting small molecules, biologics, biosimilars, cell and gene therapies, and advanced pharmaceutical products.
Enables identification of competitive strengths, service differentiation opportunities, technology adoption trends, partnership opportunities, acquisition targets, and best practice analytical capabilities, supporting strategic decision making and competitive market positioning.
Global Regulatory Landscape and Compliance Assessment
Conducted a comprehensive assessment of regulatory requirements governing pharmaceutical analytical testing services across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The analysis covered current Good Manufacturing Practices, Good Laboratory Practices, International Council for Harmonisation guidelines, analytical method validation requirements, data integrity standards, laboratory accreditation, and regulatory expectations from major health authorities. The assessment also evaluated regional regulatory differences and their impact on analytical testing operations and outsourcing decisions.
Enables CROs, pharmaceutical companies, and investors to understand evolving regulatory requirements, strengthen compliance strategies, reduce regulatory risks, prepare for inspections, and develop market entry and expansion strategies aligned with regional pharmaceutical quality standards.
Frequently Asked Questions About This Report
The global pharmaceutical analytical testing services in CRO market size was valued at USD 8.0 billion in 2025 and is estimated at USD 8.7 billion in 2026.
The global pharmaceutical analytical testing services in CRO market is expected to grow at a CAGR of 9.1% from 2026 to 2033, reaching USD 15.9 billion.
North America dominated with a 37.2% revenue share in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
The bioanalytical testing segment led with a 38.5% revenue share in 2025, while stability testing segment is fastest growing service.
The pharmaceutical companies segment led with a 45.7% revenue share in 2025, while biopharmaceutical companies segment is fastest growing end-use.
Key factors include the increasing outsourcing of analytical testing by pharmaceutical and biotechnology companies, stringent global regulatory requirements for product quality and safety, the growing development of biologics, biosimilars, and advanced therapies, expanding pharmaceutical research and development activities, and the expanding demand for specialized analytical capabilities across the drug development lifecycle.
Key players include SGS Société Générale de Surveillance SA; Worldwide Clinical Trials; Sofpromed; ClinChoice; Evotec; Eurofins Scientific; KYMOS Group; ViviaBiotech S.L.; GalChimia; TCI Laboratories; Cotecna (NEOTRON SpA); Tentamus; Enzymlogic; Pharmbiotest; UNIFARM - Research Centre; ANAPHARM EUROPE, S.L.U, among others.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs — add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
